Andreessen Horowitz leads Series A round for BigHat Biosciences

BigHat Biosciences, a novel protein therapeutics company, has raised $19 million in Series A funding.

10 February 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles